It has been reported that dasatinib enhances the inhibitory effect of tumor cell growth by trametinib, a mitogen-activated protein kinase kinase inhibitor, in vitro and in vivo in various KRAS-mutant cancer cells, including lung, breast, colon, and pancreatic cancer cells [49]. Here, KRAS is linked to cancer.